



PRESS RELEASE

FOR IMMEDIATE RELEASE

NOVEMBER 7, 2007

PHARMACY CHAIN 36.6 PRELIMINARY RESULTS OF THE FIRST NINE MONTHS OF 2007

NOVEMBER 7, 2007, MOSCOW – OAO Pharmacy Chain 36.6 [RTS:APTK;MICEX:RU14APTK1007] announces preliminary results on sales volumes and business operations for the first nine months of 2007 according to management reports.

Sales

- The consolidated sales for the first nine months of 2007 according to management accounts totaled US\$592 million, which represents 70.6% y-o-y growth.*
- Sales in the pharmacy segment amounted to US\$458.8 million, an increase of 81.6% y-o-y. In Q3 2007 retail sales amounted to US\$158.1 million, up 67.2% over the same period in 2006.
- Veropharm [RTS:VRPH, MICEX:VRFM] sales grew 31.4% and reached US\$92.9 million.
- During the first nine months of 2007 sales of the European Medical Center (EMC) totaled US\$18.7 million, up 20.6% over the same period in 2006.

<i>Thousand USD</i>	Consolidated	Retail	Veropharm	EMC
9 month 2007*	592 000	458 800	92 900	18 700
9 month 2006	346 900	252 600	70 700	15 500
<i>Change y-o-y</i>	70.6%	81.6%	31.4%	20.6%

Number of stores

- At the end of the first nine months of 2007 Pharmacy Chain 36.6 had a total of 1090 pharmacies situated in 29 regions throughout Russia. Pharmacies in the regions accounted for 45.3% of sales in the pharmaceutical retail segment.
- During Q3 2007 Pharmacy Chain 36.6 acquired nine pharmacy chains, including ZEM Pharm, Nasha Apteka, ASN, Sigma, Firma IKA, Donluy, ALS, Kompanyon and Ekoros Pharm. In total

the pharmacy chains acquired by Pharmacy Chain 36.6 include 120 pharmacies with total turnover in 2006 of approximately \$24.8 million. With the acquisition of the Kompanyon, Nasha Apteka and ASN pharmacy chains Pharmacy Chain 36.6 launched its operations in three new regions of Russia, including Stavropol region, Vladimirskaya and Ivanovskaya Territories.

- During Q3 2007, a total of 32 pharmacies were opened organically, 20 pharmacies were rebranded and 16 pharmacies were closed.

- In Q3 2007 the sixth Early Learning Center (ELC) store was opened in Moscow.

Operational results for retail business

- During the first nine months of 2007, 68.7 million purchases were made, which is 59% more than in the same period of 2006. The average receipt for pharmacies operating more than a year rose by 30.3% to US\$8.4, while the average receipt for the Moscow business unit was up 28.7% to US\$11.6 and the average receipt in regional pharmacies rose 35.9% to US\$6.2.

- Average sales floor size at the end of the first 9 months of 2007 was 60.1 square meters, down 11.6% y-o-y.

- In the first nine months of 2007, revenues per square meter of sales floor in pharmacies that had been operating for more than a year totaled US\$8100, up 29.8% y-o-y. Revenues per square meter in Moscow pharmacies were up 20.7% to US\$8800, while revenues per square meter in the regional pharmacies were up 40.6% to US\$7700.

- Sales growth (like-for-like, in US dollars) in the chain's pharmacies that had been opened or acquired prior to 1 January 2006 amounted to 28.9%. Sales growth at the mature pharmacies was primarily due to a higher average ticket size at the regional pharmacies.

	9 Months of 2007		
	Number of Pharmacies	Revenues Share	Average Sales Floor
Business Unit Moscow	374	44.5%	73.8
Business Unit Urals	360	26.7%	53.7
Business Unit South	158	13.9%	37.3
Business Unit Volga Region	132	9.9%	58.3
Business Unit North-West	32	2.9%	69.6
Business Unit Western Siberia	34	2.2%	44.8
<i>Total in the Chain:</i>	1090		60.1

Operational Performance in Pharmacy Lifetime Groups:

	9 Months of 2007		
	Number of Pharmacies	Revenues Share	Average Receipt (US\$)
Pharmacies opened prior to Jan 01, 2006	389	54.8%	8.6
Pharmacies opened after Jan 01, 2006	701	45.2%	5.2
<i>Total in the Chain:</i>	1090		6.7

Debt

- As of the end of the first 9 months of 2007, the net debt of Pharmacy Chain 36.6 stood at US\$274.3 million.

- As of the end of the first 9 months of 2007, Veropharm's debt stood at US\$23.9 million.

** here and hereinafter financial indicators may significantly differ from the IFRS consolidated data.*

For further information please contact:

Maria Zhog,
*Corporate Communications &
Investor Relations Manager*

*mzhog@oao366.ru
Tel. (+7495) 792 52 07
(+7495) 797 86 86 ext.1534*

or go to the Company's web-site

*www.pharmacychain366.ru
www.oao366.ru*

Notes to the Editor:

Pharmacy Chain 36.6 is the first public national health and beauty retailer listed in the "B"-list on RTS (ticker: APTK) and off-list on MICEX (ticker: RU14APTK1007). Market capitalisation (not counting the additional placement of shares) as of 06.11.07 was USD 604 million based on RTS share prices.

Pharmacy Chain 36.6 operates over 1090 stores in 29 regions and 90 cities in Russia.

OA O Veropharm, the Company's generics subsidiary, is one of Russia's top five manufacturers (according to Pharmexpert research). Veropharm's shares are traded in the "B"-list on RTS (ticker: VRPH) and off-list on MICEX (ticker: VRFM). Market capitalisation as of 06.11.07 was USD 469,7 million based on RTS share prices.

ZAO Apteki 36.6 is one of the founding members of the Russian Association of Pharmacy Chains (RAPC).

Pharmacy Chain 36.6 is a participating member of the international retailers' organizations – NRF and NACDS. Pharmacy Chain 36.6 employs 12,000 people.

THIS DOCUMENT IS NOT AN ADVERTISEMENT OF SECURITIES IN THE RUSSIAN FEDERATION AND IS NOT AN OFFER TO SELL OR AN INVITATION TO MAKE OFFERS TO PURCHASE ANY SECURITIES IN THE RUSSIAN FEDERATION.

NOT FOR RELEASE DIRECTLY OR INDIRECTLY IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

The securities referred to herein have not been and will not be registered under the US Securities Act of 1933 as amended (the "Securities Act") and may not be offered or sold in the United States or to US persons unless the securities are registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States.

This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom. (b) persons who have professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (c) high net worth companies, unincorporated associations and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49 of the Order (all such persons together being referred to as "relevant persons"). The securities referred to in this press release and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.